Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women

Rowan T. Chlebowski, Garnet L. Anderson, Margery Gass, Dorothy S. Lane, Aaron K. Aragaki, Lewis H. Kuller, JoAnn E. Manson, Marcia L. Stefanick, Judith Ockene, Gloria E. Sarto, Karen C. Johnson, Jean Wactawski-Wende, Peter M. Ravdin, Robert Schenken, Susan L. Hendrix, Aleksandar Rajkovic, Thomas E. Rohan, Shagufta Yasmeen, Ross L. Prentice

Research output: Contribution to journalArticle

372 Citations (Scopus)

Abstract

Context: In the Women's Health Initiative randomized, placebo-controlled trial of estrogen plus progestin, after a mean intervention time of 5.6 (SD, 1.3) years (range, 3.7-8.6 years) and a mean follow-up of 7.9 (SD, 1.4) years, breast cancer incidence was increased among women who received combined hormone therapy. Breast cancer mortality among participants in the trial has not been previously reported. Objective: To determine the effects of therapy with estrogen plus progestin on cumulative breast cancer incidence and mortality after a total mean follow-up of 11.0 (SD, 2.7) years, through August 14, 2009. Design, Setting, and Participants: A total of 16 608 postmenopausal women aged 50 to 79 years with no prior hysterectomy from 40 US clinical centers were randomly assigned to receive combined conjugated equine estrogens, 0.625 mg/d, plus medroxyprogesterone acetate, 2.5 mg/d, or placebo pill. After the original trial completion date (March 31, 2005), reconsent was required for continued follow-up for breast cancer incidence and was obtained from 12 788 (83%) of the surviving participants. Main Outcome Measures: Invasive breast cancer incidence and breast cancer mortality. Results: In intention-to-treat analyses including all randomized participants and censoring those not consenting to additional follow-up on March 31, 2005, estrogen plus progestin was associated with more invasive breast cancers compared with placebo (385 cases [0.42% per year] vs 293 cases [0.34% per year]; hazard ratio [HR], 1.25;95% confidence interval [CI], 1.07-1.46; P=.004). Breast cancers in the estrogen-plus-progestin group were similar in histology and grade to breast cancers in the placebo group but were more likely to be node-positive (81 [23.7%] vs43[16.2%], respectively;HR,1. 78;95%CI, 1.23-2.58; P=.03). There were more deaths directly attributed to breast cancer (25 deaths [0.03% per year] vs 12 deaths [0.01% per year]; HR, 1.96;95%CI, 1.00-4.04; P=.049) as well as more deaths from all causes occurring after a breast cancer diagnosis (51 deaths [0.05% per year] vs 31 deaths [0.03% per year]; HR, 1.57; 95% CI, 1.01-2.48; P=.045) among women who received estrogen plus progestin compared with women in the placebo group. Conclusions: Estrogen plus progestin was associated with greater breast cancer incidence, and the cancers are more commonly node-positive. Breast cancer mortality also appears to be increased with combined use of estrogen plus progestin. Trial Registration clinicaltrials.gov Identifier: NCT00000611.

Original languageEnglish (US)
Pages (from-to)1684-1692
Number of pages9
JournalJAMA - Journal of the American Medical Association
Volume304
Issue number15
DOIs
StatePublished - Oct 20 2010

Fingerprint

Progestins
Estrogens
Breast Neoplasms
Mortality
Incidence
Placebos
Confidence Intervals
Conjugated (USP) Estrogens
Medroxyprogesterone Acetate
Intention to Treat Analysis
Women's Health
Hysterectomy
Cause of Death
Histology
Randomized Controlled Trials

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Chlebowski, R. T., Anderson, G. L., Gass, M., Lane, D. S., Aragaki, A. K., Kuller, L. H., ... Prentice, R. L. (2010). Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA - Journal of the American Medical Association, 304(15), 1684-1692. https://doi.org/10.1001/jama.2010.1500

Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. / Chlebowski, Rowan T.; Anderson, Garnet L.; Gass, Margery; Lane, Dorothy S.; Aragaki, Aaron K.; Kuller, Lewis H.; Manson, JoAnn E.; Stefanick, Marcia L.; Ockene, Judith; Sarto, Gloria E.; Johnson, Karen C.; Wactawski-Wende, Jean; Ravdin, Peter M.; Schenken, Robert; Hendrix, Susan L.; Rajkovic, Aleksandar; Rohan, Thomas E.; Yasmeen, Shagufta; Prentice, Ross L.

In: JAMA - Journal of the American Medical Association, Vol. 304, No. 15, 20.10.2010, p. 1684-1692.

Research output: Contribution to journalArticle

Chlebowski, RT, Anderson, GL, Gass, M, Lane, DS, Aragaki, AK, Kuller, LH, Manson, JE, Stefanick, ML, Ockene, J, Sarto, GE, Johnson, KC, Wactawski-Wende, J, Ravdin, PM, Schenken, R, Hendrix, SL, Rajkovic, A, Rohan, TE, Yasmeen, S & Prentice, RL 2010, 'Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women', JAMA - Journal of the American Medical Association, vol. 304, no. 15, pp. 1684-1692. https://doi.org/10.1001/jama.2010.1500
Chlebowski, Rowan T. ; Anderson, Garnet L. ; Gass, Margery ; Lane, Dorothy S. ; Aragaki, Aaron K. ; Kuller, Lewis H. ; Manson, JoAnn E. ; Stefanick, Marcia L. ; Ockene, Judith ; Sarto, Gloria E. ; Johnson, Karen C. ; Wactawski-Wende, Jean ; Ravdin, Peter M. ; Schenken, Robert ; Hendrix, Susan L. ; Rajkovic, Aleksandar ; Rohan, Thomas E. ; Yasmeen, Shagufta ; Prentice, Ross L. / Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. In: JAMA - Journal of the American Medical Association. 2010 ; Vol. 304, No. 15. pp. 1684-1692.
@article{85c7ccbd011847f98b670a5696e0be91,
title = "Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women",
abstract = "Context: In the Women's Health Initiative randomized, placebo-controlled trial of estrogen plus progestin, after a mean intervention time of 5.6 (SD, 1.3) years (range, 3.7-8.6 years) and a mean follow-up of 7.9 (SD, 1.4) years, breast cancer incidence was increased among women who received combined hormone therapy. Breast cancer mortality among participants in the trial has not been previously reported. Objective: To determine the effects of therapy with estrogen plus progestin on cumulative breast cancer incidence and mortality after a total mean follow-up of 11.0 (SD, 2.7) years, through August 14, 2009. Design, Setting, and Participants: A total of 16 608 postmenopausal women aged 50 to 79 years with no prior hysterectomy from 40 US clinical centers were randomly assigned to receive combined conjugated equine estrogens, 0.625 mg/d, plus medroxyprogesterone acetate, 2.5 mg/d, or placebo pill. After the original trial completion date (March 31, 2005), reconsent was required for continued follow-up for breast cancer incidence and was obtained from 12 788 (83{\%}) of the surviving participants. Main Outcome Measures: Invasive breast cancer incidence and breast cancer mortality. Results: In intention-to-treat analyses including all randomized participants and censoring those not consenting to additional follow-up on March 31, 2005, estrogen plus progestin was associated with more invasive breast cancers compared with placebo (385 cases [0.42{\%} per year] vs 293 cases [0.34{\%} per year]; hazard ratio [HR], 1.25;95{\%} confidence interval [CI], 1.07-1.46; P=.004). Breast cancers in the estrogen-plus-progestin group were similar in histology and grade to breast cancers in the placebo group but were more likely to be node-positive (81 [23.7{\%}] vs43[16.2{\%}], respectively;HR,1. 78;95{\%}CI, 1.23-2.58; P=.03). There were more deaths directly attributed to breast cancer (25 deaths [0.03{\%} per year] vs 12 deaths [0.01{\%} per year]; HR, 1.96;95{\%}CI, 1.00-4.04; P=.049) as well as more deaths from all causes occurring after a breast cancer diagnosis (51 deaths [0.05{\%} per year] vs 31 deaths [0.03{\%} per year]; HR, 1.57; 95{\%} CI, 1.01-2.48; P=.045) among women who received estrogen plus progestin compared with women in the placebo group. Conclusions: Estrogen plus progestin was associated with greater breast cancer incidence, and the cancers are more commonly node-positive. Breast cancer mortality also appears to be increased with combined use of estrogen plus progestin. Trial Registration clinicaltrials.gov Identifier: NCT00000611.",
author = "Chlebowski, {Rowan T.} and Anderson, {Garnet L.} and Margery Gass and Lane, {Dorothy S.} and Aragaki, {Aaron K.} and Kuller, {Lewis H.} and Manson, {JoAnn E.} and Stefanick, {Marcia L.} and Judith Ockene and Sarto, {Gloria E.} and Johnson, {Karen C.} and Jean Wactawski-Wende and Ravdin, {Peter M.} and Robert Schenken and Hendrix, {Susan L.} and Aleksandar Rajkovic and Rohan, {Thomas E.} and Shagufta Yasmeen and Prentice, {Ross L.}",
year = "2010",
month = "10",
day = "20",
doi = "10.1001/jama.2010.1500",
language = "English (US)",
volume = "304",
pages = "1684--1692",
journal = "JAMA - Journal of the American Medical Association",
issn = "0002-9955",
publisher = "American Medical Association",
number = "15",

}

TY - JOUR

T1 - Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women

AU - Chlebowski, Rowan T.

AU - Anderson, Garnet L.

AU - Gass, Margery

AU - Lane, Dorothy S.

AU - Aragaki, Aaron K.

AU - Kuller, Lewis H.

AU - Manson, JoAnn E.

AU - Stefanick, Marcia L.

AU - Ockene, Judith

AU - Sarto, Gloria E.

AU - Johnson, Karen C.

AU - Wactawski-Wende, Jean

AU - Ravdin, Peter M.

AU - Schenken, Robert

AU - Hendrix, Susan L.

AU - Rajkovic, Aleksandar

AU - Rohan, Thomas E.

AU - Yasmeen, Shagufta

AU - Prentice, Ross L.

PY - 2010/10/20

Y1 - 2010/10/20

N2 - Context: In the Women's Health Initiative randomized, placebo-controlled trial of estrogen plus progestin, after a mean intervention time of 5.6 (SD, 1.3) years (range, 3.7-8.6 years) and a mean follow-up of 7.9 (SD, 1.4) years, breast cancer incidence was increased among women who received combined hormone therapy. Breast cancer mortality among participants in the trial has not been previously reported. Objective: To determine the effects of therapy with estrogen plus progestin on cumulative breast cancer incidence and mortality after a total mean follow-up of 11.0 (SD, 2.7) years, through August 14, 2009. Design, Setting, and Participants: A total of 16 608 postmenopausal women aged 50 to 79 years with no prior hysterectomy from 40 US clinical centers were randomly assigned to receive combined conjugated equine estrogens, 0.625 mg/d, plus medroxyprogesterone acetate, 2.5 mg/d, or placebo pill. After the original trial completion date (March 31, 2005), reconsent was required for continued follow-up for breast cancer incidence and was obtained from 12 788 (83%) of the surviving participants. Main Outcome Measures: Invasive breast cancer incidence and breast cancer mortality. Results: In intention-to-treat analyses including all randomized participants and censoring those not consenting to additional follow-up on March 31, 2005, estrogen plus progestin was associated with more invasive breast cancers compared with placebo (385 cases [0.42% per year] vs 293 cases [0.34% per year]; hazard ratio [HR], 1.25;95% confidence interval [CI], 1.07-1.46; P=.004). Breast cancers in the estrogen-plus-progestin group were similar in histology and grade to breast cancers in the placebo group but were more likely to be node-positive (81 [23.7%] vs43[16.2%], respectively;HR,1. 78;95%CI, 1.23-2.58; P=.03). There were more deaths directly attributed to breast cancer (25 deaths [0.03% per year] vs 12 deaths [0.01% per year]; HR, 1.96;95%CI, 1.00-4.04; P=.049) as well as more deaths from all causes occurring after a breast cancer diagnosis (51 deaths [0.05% per year] vs 31 deaths [0.03% per year]; HR, 1.57; 95% CI, 1.01-2.48; P=.045) among women who received estrogen plus progestin compared with women in the placebo group. Conclusions: Estrogen plus progestin was associated with greater breast cancer incidence, and the cancers are more commonly node-positive. Breast cancer mortality also appears to be increased with combined use of estrogen plus progestin. Trial Registration clinicaltrials.gov Identifier: NCT00000611.

AB - Context: In the Women's Health Initiative randomized, placebo-controlled trial of estrogen plus progestin, after a mean intervention time of 5.6 (SD, 1.3) years (range, 3.7-8.6 years) and a mean follow-up of 7.9 (SD, 1.4) years, breast cancer incidence was increased among women who received combined hormone therapy. Breast cancer mortality among participants in the trial has not been previously reported. Objective: To determine the effects of therapy with estrogen plus progestin on cumulative breast cancer incidence and mortality after a total mean follow-up of 11.0 (SD, 2.7) years, through August 14, 2009. Design, Setting, and Participants: A total of 16 608 postmenopausal women aged 50 to 79 years with no prior hysterectomy from 40 US clinical centers were randomly assigned to receive combined conjugated equine estrogens, 0.625 mg/d, plus medroxyprogesterone acetate, 2.5 mg/d, or placebo pill. After the original trial completion date (March 31, 2005), reconsent was required for continued follow-up for breast cancer incidence and was obtained from 12 788 (83%) of the surviving participants. Main Outcome Measures: Invasive breast cancer incidence and breast cancer mortality. Results: In intention-to-treat analyses including all randomized participants and censoring those not consenting to additional follow-up on March 31, 2005, estrogen plus progestin was associated with more invasive breast cancers compared with placebo (385 cases [0.42% per year] vs 293 cases [0.34% per year]; hazard ratio [HR], 1.25;95% confidence interval [CI], 1.07-1.46; P=.004). Breast cancers in the estrogen-plus-progestin group were similar in histology and grade to breast cancers in the placebo group but were more likely to be node-positive (81 [23.7%] vs43[16.2%], respectively;HR,1. 78;95%CI, 1.23-2.58; P=.03). There were more deaths directly attributed to breast cancer (25 deaths [0.03% per year] vs 12 deaths [0.01% per year]; HR, 1.96;95%CI, 1.00-4.04; P=.049) as well as more deaths from all causes occurring after a breast cancer diagnosis (51 deaths [0.05% per year] vs 31 deaths [0.03% per year]; HR, 1.57; 95% CI, 1.01-2.48; P=.045) among women who received estrogen plus progestin compared with women in the placebo group. Conclusions: Estrogen plus progestin was associated with greater breast cancer incidence, and the cancers are more commonly node-positive. Breast cancer mortality also appears to be increased with combined use of estrogen plus progestin. Trial Registration clinicaltrials.gov Identifier: NCT00000611.

UR - http://www.scopus.com/inward/record.url?scp=77958138780&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77958138780&partnerID=8YFLogxK

U2 - 10.1001/jama.2010.1500

DO - 10.1001/jama.2010.1500

M3 - Article

C2 - 20959578

AN - SCOPUS:77958138780

VL - 304

SP - 1684

EP - 1692

JO - JAMA - Journal of the American Medical Association

JF - JAMA - Journal of the American Medical Association

SN - 0002-9955

IS - 15

ER -